ZFIN ID: ZDB-FISH-150901-18514
Fish name: vu17Tg; vu19Tg
Genotype: vu17Tg; vu19Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by vu17Tg; vu19Tg
No data available
GENE EXPRESSION
Gene expression in vu17Tg; vu19Tg
RNA expression
Expressed Gene Structure Conditions Figures
sox10 control Fig. 2Fig. 5 from Kucenas et al., 2008
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-sox10 sox10 control Fig. 2Fig. 5 from Kucenas et al., 2008
PHENOTYPE
Phenotype in vu17Tg; vu19Tg
Phenotype Conditions Figures
glioblast (sensu Vertebrata) cell population proliferation normal occurrence, normal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal standard conditions Figure 6 with image from Danesin et al., 2021
spinal cord dorsal region has fewer parts of type glioblast (sensu Vertebrata), abnormal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
spinal cord dorsal region has normal numbers of parts of type glioblast (sensu Vertebrata), normal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
spinal cord glial cell migration decreased process quality, abnormal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal standard conditions Figure 6 with image from Danesin et al., 2021
whole organism morphology, normal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
whole organism normal length, normal chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021

CITATIONS  (12)